191 related articles for article (PubMed ID: 26126066)
1. The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.
Mangia A; Caldarola L; Dell'Endice S; Scarpi E; Saragoni L; Monti M; Santini D; Brunetti O; Simone G; Silvestris N
Cancer Biol Ther; 2015; 16(8):1140-7. PubMed ID: 26126066
[TBL] [Abstract][Full Text] [Related]
2. NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
Saponaro C; Vagheggini A; Scarpi E; Centonze M; Catacchio I; Popescu O; Pastena MI; Giotta F; Silvestris N; Mangia A
J Exp Clin Cancer Res; 2018 May; 37(1):96. PubMed ID: 29716631
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Qiu ZQ; Qiu ZR
Asian Pac J Cancer Prev; 2015; 16(8):3447-50. PubMed ID: 25921160
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
7. Nuclear NHERF1 expression as a prognostic marker in breast cancer.
Paradiso A; Scarpi E; Malfettone A; Addati T; Giotta F; Simone G; Amadori D; Mangia A
Cell Death Dis; 2013 Nov; 4(11):e904. PubMed ID: 24201803
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Eltweri AM; Thomas AL; Chung WY; Morgan B; Thompson J; Dennison AR; Bowrey DJ
Anticancer Res; 2019 Feb; 39(2):853-861. PubMed ID: 30711967
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between the expression of hypoxia-inducible factor-1alpha and chemotherapy response in gastric carcinoma].
Wu Q; Li ZS; Li DW; Peng ZH; Yang ZR
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):498-501. PubMed ID: 19742344
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype.
Malfettone A; Silvestris N; Paradiso A; Mattioli E; Simone G; Mangia A
Exp Mol Pathol; 2012 Jun; 92(3):296-303. PubMed ID: 22440733
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Rosati G; Cella CA; Cavanna L; Codecà C; Prisciandaro M; Mosconi S; Luchena G; Silvestris N; Bernardini I; Casaretti R; Zoratto F; Amoroso D; Ciarlo A; Barni S; Cascinu S; Davite C; Di Sanzo A; Casolaro A; Bilancia D; Labianca R
Gastric Cancer; 2022 Jul; 25(4):783-793. PubMed ID: 35352176
[TBL] [Abstract][Full Text] [Related]
14. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.
Chen J; Ding Z; Peng Y; Pan F; Li J; Zou L; Zhang Y; Liang H
PLoS One; 2014; 9(6):e98882. PubMed ID: 24901645
[TBL] [Abstract][Full Text] [Related]
15. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
16. [Expression of hypoxia-inducible factor 1α in gastric cancer and its clinical signficance].
Wu YL; Hu LN; Zheng CD; Sun RC; Zhang SX; Yan Q; Li YX
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1418-23. PubMed ID: 27266349
[TBL] [Abstract][Full Text] [Related]
17. NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors.
Georgescu MM; Mobley BC; Orr BA; Shang P; Lehman NL; Zhu X; O'Neill TJ; Rajaram V; Hatanpaa KJ; Timmons CF; Raisanen JM
Acta Neuropathol Commun; 2016 May; 4(1):55. PubMed ID: 27229317
[TBL] [Abstract][Full Text] [Related]
18. NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Mangia A; Scarpi E; Partipilo G; Schirosi L; Opinto G; Giotta F; Simone G
Oncotarget; 2017 Sep; 8(39):65730-65742. PubMed ID: 29029467
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
20. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M
Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
